EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparison of Rosuvastatin and Rosuvastatin Plus Ezetimibe in Reducing Low-Density Lipoproteins

Muhammad Salah Ud Din, Muhammad Adnan, Ihtisham Saeed, Abidullah, Nazeef Ullah, Noor Faraz

Journal of Health, Wellness and Community Research · 15.01.2026 · e1375

DOI: 10.61919/bekv1p88 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Health, Wellness and Community Research, online erschienen am 15.01.2026. Verfasst von Muhammad Salah Ud Din und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dyslipidaemia, particularly elevated low-density lipoprotein cholesterol (LDL-C), is a leading modifiable risk factor for cardiovascular disease (CVD), which accounts for approximately 30–40% of adult mortality in Pakistan. Despite statin availability, LDL-C target attainment remains poor in high-risk Pakistani patients, necessitating evaluation of combination lipid-lowering strategies.

Objective

To compare the efficacy and safety of rosuvastatin monotherapy versus rosuvastatin-ezetimibe combination therapy in reducing LDL-C among high-risk cardiovascular patients at a tertiary care centre in Peshawar, Pakistan.

Methods

A retrospective cohort study was conducted between June 2022 and June 2023 (n = 150; 75 per arm). Adults aged 30–75 years with hypercholesterolaemia (LDL-C ≥100 mg/dL) and established CVD risk factors were included. Fasting lipid profiles were recorded at baseline and at 12 weeks. The primary outcome was absolute and proportional LDL-C reduction; secondary outcomes included changes in total cholesterol, triglycerides, HDL-C, and apolipoprotein B (ApoB). Between-group comparisons were performed using independent-samples t-tests, with Bonferroni correction applied for secondary outcomes.

Results

Baseline LDL-C was comparable between groups (144.12 ± 26.12 vs 142.46 ± 24.98 mg/dL; p = 0.681). At 12 weeks, LDL-C decreased to 91.60 ± 28.90 mg/dL in the rosuvastatin arm (36.5% reduction) and to 88.75 ± 29.73 mg/dL in the combination arm (37.7% reduction); the between-group difference was 2.85 mg/dL (95% CI: 0.39–5.31; p = 0.0234). Neither group achieved the guideline LDL-C target of

Zitieren

APA

Din, M. S. U., Adnan, M., Saeed, I., Abidullah, Ullah, N., & Faraz, N. (2026). Comparison of Rosuvastatin and Rosuvastatin Plus Ezetimibe in Reducing Low-Density Lipoproteins. Journal of Health, Wellness and Community Research, e1375. https://doi.org/10.61919/bekv1p88

Vancouver

Din MSU, Adnan M, Saeed I, Abidullah, Ullah N, Faraz N. Comparison of Rosuvastatin and Rosuvastatin Plus Ezetimibe in Reducing Low-Density Lipoproteins. Journal of Health, Wellness and Community Research. 2026:e1375. doi:10.61919/bekv1p88

BibTeX
@article{Din2026,
  author = {Din, Muhammad Salah Ud and Adnan, Muhammad and Saeed, Ihtisham and Abidullah and Ullah, Nazeef and Faraz, Noor},
  title = {Comparison of Rosuvastatin and Rosuvastatin Plus Ezetimibe in Reducing Low-Density Lipoproteins},
  journal = {Journal of Health, Wellness and Community Research},
  year = {2026},
  pages = {e1375},
  doi = {10.61919/bekv1p88}
}
Kostenlos starten →